AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17889468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15002002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (trained in hypertension guidelines)
Number of subjects: 4083
Study 15002002 — intervention group
Group type: COMPARATOR
Intervention: Reference group (monitored for efficacy of training)
Number of subjects: 4083
Study 15002002 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 4083
Study 15857101 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous periodontal ligament (PDL) grafts
Number of subjects: 10
Study 15857101 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap procedure without graft
Number of subjects: 10
Study 10589755 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99 low dose (10 mg/m2)
Number of subjects: 40
Study 10589755 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99 high dose (20 mg/m2)
Number of subjects: 40
Study 10589755 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC D‐99 (combined results)
Number of subjects: 40
Study 8919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of deployed personnel
Number of subjects: 383
Study 8919705 — intervention group
Group type: EXPERIMENTAL
Intervention: Families of deployed personnel
Number of subjects: 383
Study 8919705 — intervention group
Group type: COMPARATOR
Intervention: Children of nondeployed personnel
Number of subjects: 383
Study 1928220 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA infusions (50 mg/kg over three hours)
Number of subjects: 14
Study 1928220 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 14
Study 6130677 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg, single oral dose)
Number of subjects: 6
Study 31914959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamoja Tunaweza (a locally adapted version of Trauma-focused Cognitive Behavioral Therapy)
Number of subjects: 1200
Study 31914959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamoja Tunaweza
Number of subjects: 1200
Study 30210115 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan plus rebamipide (V group)
Number of subjects: 84
Study 30210115 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole plus rebamipide (E group)
Number of subjects: 84
Study 30672193 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-letting and cupping therapy combined with basic treatment for 2 weeks, 3 times a week, once every other day.
Number of subjects: 60
Study 30672193 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment including internal treatment, acupuncture, and rehabilitation for 2 weeks, 6 times a week, once a day.
Number of subjects: 60
Study 27113979 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 20
Study 27113979 — intervention group
Group type: COMPARATOR
Intervention: CRT
Number of subjects: 20
Study 27113979 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 20
Study 25140931 — intervention group
Group type: EXPERIMENTAL
Intervention: BL‐rTMS
Number of subjects: 58
Study 25140931 — intervention group
Group type: COMPARATOR
Intervention: HF‐rTMS
Number of subjects: 58
Study 22406052 — intervention group
Group type: EXPERIMENTAL
Intervention: Group integrated cognitive‐behavioral therapy for 6 months
Number of subjects: 237
Study 22406052 — intervention group
Group type: COMPARATOR
Intervention: Twelve‐step facilitation
Number of subjects: 237
Study 20705946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing
Number of subjects: 10
Study 20705946 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe curls
Number of subjects: 10
Study 20705946 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 10
Study 20705946 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 10
Study 20705946 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 10
Study 20705946 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study 18823200 — intervention group
Group type: EXPERIMENTAL
Intervention: Face inversion effect for vertical shifts of the eyes alone
Number of subjects: 0
Study 18823200 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention
Number of subjects: 0
Study 18823200 — intervention group
Group type: EXPERIMENTAL
Intervention: Face inversion
Number of subjects: 0
Study 16022729 — intervention group
Group type: EXPERIMENTAL
Intervention: GORD (G+) group
Number of subjects: 150
Study 16022729 — intervention group
Group type: COMPARATOR
Intervention: No GORD (G-) group
Number of subjects: 150
Study 16022729 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 12434950 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO and G-CSF
Number of subjects: 68
Study 12434950 — intervention group
Group type: COMPARATOR
Intervention: Control (G-CSF only)
Number of subjects: 68
Study 10357341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium (MIV)
Number of subjects: 50
Study 10357341 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (SUCC)
Number of subjects: 50
Study 10357341 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (ATR)
Number of subjects: 50
Study 10357341 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (ROC)
Number of subjects: 50
Study 10357341 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC)
Number of subjects: 50
Study 7792736 — intervention group
Group type: EXPERIMENTAL
Intervention: diet S (C18:0)
Number of subjects: 15
Study 7792736 — intervention group
Group type: COMPARATOR
Intervention: diet ML (C12:0 + C14:0)
Number of subjects: 15
Study 2022441 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03% eye drops
Number of subjects: 0
Study 2022441 — intervention group
Group type: COMPARATOR
Intervention: Vehicle application (placebo)
Number of subjects: 0
Study 31983575 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA-2291 (Atreleuton) 100 mg
Number of subjects: 54
Study 31983575 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA-2291 (Atreleuton) (25 mg, 50 mg)
Number of subjects: 54
Study 31983575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31541251 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated implant (CI; Synovex‐One Feedlot)
Number of subjects: 24
Study 31541251 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants (both CI and NC)
Number of subjects: 24
Study 31541251 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coated implant (NC; Synovex‐PLUS)
Number of subjects: 24
Study 31541251 — intervention group
Group type: COMPARATOR
Intervention: No implant (NI)
Number of subjects: 24
Study 27680592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (8 g/d)
Number of subjects: 36
Study 27680592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 8 g/d)
Number of subjects: 36
Study 26383207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental
Number of subjects: 100
Study 26383207 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study 23290598 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg orally daily for 26 weeks
Number of subjects: 81
Study 23290598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 21240683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 4 mg every 4 weeks
Number of subjects: 55
Study 21240683 — intervention group
Group type: COMPARATOR
Intervention: Oral ibandronate (IBA) 50 mg/day
Number of subjects: 55
Study 19126811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (n = 60) or globus pallidus (n = 61)
Number of subjects: 255
Study 19126811 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation
Number of subjects: 255
Study 19126811 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (n = 134)
Number of subjects: 255
Study 16954546 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic doses of 2, 1, and 0.5 mCi (74, 37, and 18.5 MBq)
Number of subjects: 80
Study 16954546 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic doses of 150 and 30 mCi (5,550 and 1,110 MBq)
Number of subjects: 80
Study 16954546 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic (131)I
Number of subjects: 80
Study 14764782 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise for 6 months
Number of subjects: 18
Study 11562514 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose sulfited wine challenge (300 ppm)
Number of subjects: 42
Study 11562514 — intervention group
Group type: COMPARATOR
Intervention: Double blind, placebo controlled challenge with varying sulfite levels
Number of subjects: 42
Study 11562514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose sulfited wine challenge
Number of subjects: 42
Study 9240359 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive employment
Number of subjects: 143
Study 9240359 — intervention group
Group type: COMPARATOR
Intervention: Unemployed patients
Number of subjects: 143
Study 8119458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical laser vaporization treatment
Number of subjects: 46
Study 8119458 — intervention group
Group type: COMPARATOR
Intervention: Follow-up without therapy (Control)
Number of subjects: 46
Study 3630583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2 mg kg‐1
Number of subjects: 40
Study 3630583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2.5 mg kg‐1
Number of subjects: 40
Study 3630583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 3 mg kg‐1
Number of subjects: 40
Study 3630583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 3.5 mg kg‐1
Number of subjects: 40
Study 3630583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ranitidine)
Number of subjects: 40
Study 3630583 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ranitidine (2-3.5 mg kg‐1)
Number of subjects: 40
Study 30945490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu-Moxi group (acupuncture plus herbal-cake partitioned moxibustion)
Number of subjects: 78
Study 30945490 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine acupuncture)
Number of subjects: 78
Study 30945490 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 28790270 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid doppler echo screening
Number of subjects: 0
Study 28790270 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery intervention (carotid endarterectomy or carotid artery stenting)
Number of subjects: 0
Study 28790270 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 0
Study 26352376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 47
Study 26352376 — intervention group
Group type: COMPARATOR
Intervention: Digital palpation
Number of subjects: 47
Study 24118425 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-narrowband UVB (P-NBUVB)
Number of subjects: 45
Study 24118425 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UVB (NBUVB)
Number of subjects: 45
Study 21404217 — intervention group
Group type: EXPERIMENTAL
Intervention: MC X11 ASP IOL
Number of subjects: 28
Study 21404217 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IQ IOL
Number of subjects: 28
Study 19303768 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide, 30 mg as an intramuscular injection once every 4 weeks for up to 2 years
Number of subjects: 272
Study 19303768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 19303768 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide
Number of subjects: 272
Study 16791019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (400,000 IU within 96 hours post-partum)
Number of subjects: 14110
Study 16791019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14110
Study 16791019 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation among women with low serum retinol (< 0.7 micromol/l)
Number of subjects: 14110
Study 16791019 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe anaemia (haemoglobin < 70 g/l)
Number of subjects: 14110
Study 16791019 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 14110
Study 14501739 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 61
Study 14501739 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 61
Study 10697447 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide, 1200 mcg daily for 6 months followed by 800 mcg daily for 30 months
Number of subjects: 290
Study 10697447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 9377904 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth standards based on birth weight, birth length and birth head circumference
Number of subjects: 0
Study 8222097 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (5000-U intravenous bolus followed by a perfusion titrated to the APTT)
Number of subjects: 484
Study 8222097 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg bid)
Number of subjects: 484
Study 8222097 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 484
Study 3078624 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg preoperatively and 0.25 mg/kg/day for 48 hours postoperatively)
Number of subjects: 36
Study 3078624 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (0.5 mg/kg preoperatively and 0.25 mg/kg/day for 48 hours postoperatively)
Number of subjects: 36
Study 30334633 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneously at baseline, Weeks 1, 2, 3, and 4, and every 4 weeks thereafter
Number of subjects: 30
Study 30334633 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 30
Study 30768397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy
Number of subjects: 684
Study 30768397 — intervention group
Group type: COMPARATOR
Intervention: Management as usual
Number of subjects: 684
Study 28295794 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message intervention
Number of subjects: 67
Study 25451073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube drainage
Number of subjects: 40
Study 25451073 — intervention group
Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 40
Study 24366788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.5% concentration, 0.5 ml/kg)
Number of subjects: 40
Study 24366788 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.5% concentration, 0.5 ml/kg)
Number of subjects: 40
Study 24366788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40
Study 24366788 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study 21970660 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet (T)
Number of subjects: 24
Study 21970660 — intervention group
Group type: COMPARATOR
Intervention: Branded formulations of both drugs co-administered in separate tablets (R)
Number of subjects: 24
Study 19527695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (serial subtractions of 3s) during preferred walking pace
Number of subjects: 21
Study 19527695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (serial subtractions of 3s) during fast walking
Number of subjects: 21
Study 19527695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task (visuo-spatial decision task) during fast walking
Number of subjects: 21
Study 19527695 — intervention group
Group type: COMPARATOR
Intervention: Cognitive task (serial subtractions of 3s)
Number of subjects: 21
Study 16674968 — intervention group
Group type: EXPERIMENTAL
Intervention: Prereading children articulating shared heads, codas, and onsets
Number of subjects: 91
Study 16674968 — intervention group
Group type: EXPERIMENTAL
Intervention: Precocious readers articulating shared rimes
Number of subjects: 91
Study 16674968 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection task for rimes and heads
Number of subjects: 91
Study 14960254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 209
Study 14960254 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 209
Study 11412554 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic minimal intervention
Number of subjects: 304
Study 11412554 — intervention group
Group type: COMPARATOR
Intervention: One-off medical counselling
Number of subjects: 304
Study 11412554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with nicotine patches (11% nicotine)
Number of subjects: 304
Study 9562759 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of long-acting corticosteroid
Number of subjects: 55
Study 7913738 — intervention group
Group type: EXPERIMENTAL
Intervention: Talipexole
Number of subjects: 13
Study 7913738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2603190 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand washing intervention with 2 bars of plain soap
Number of subjects: 494
Study 2603190 — intervention group
Group type: COMPARATOR
Intervention: Control group following customary practice
Number of subjects: 494
Study 4599859 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 62
Study 4599859 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 62
Study 30152737 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to an RIA recording several times before and during the session
Number of subjects: 60
Study 30152737 — intervention group
Group type: EXPERIMENTAL
Intervention: In-session RIA intervention
Number of subjects: 60
Study 30152737 — intervention group
Group type: COMPARATOR
Intervention: Listening to relaxing music (control condition)
Number of subjects: 60
Study 27062956 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey consumption (2.5 g/kg body weight per dose, twice weekly for 12 weeks)
Number of subjects: 40
Study 27062956 — intervention group
Group type: COMPARATOR
Intervention: Honey withdrawal (after intervention)
Number of subjects: 40
Study 25898184 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Kids to Cope with Anger (TKC‐A) program
Number of subjects: 179
Study 25898184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 179
Study 23713298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50
Study 23713298 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study 20517177 — intervention group
Group type: EXPERIMENTAL
Intervention: Evl trough levels >= 3 ng/mL
Number of subjects: 92
Study 20517177 — intervention group
Group type: COMPARATOR
Intervention: Evl trough levels < 3 ng/mL
Number of subjects: 92
Study 20517177 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Tac
Number of subjects: 92
Study 20517177 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Tac
Number of subjects: 92
Study 20517177 — intervention group
Group type: EXPERIMENTAL
Intervention: Evl and Tac levels
Number of subjects: 92
Study 20517177 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 92
Study 19057271 — intervention group
Group type: EXPERIMENTAL
Intervention: erlotinib (150 mg PO per day)
Number of subjects: 311
Study 17144179 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of racial categories in medicine as an interim step
Number of subjects: 0
Study 17144179 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up inquiry into factors underlying race-correlated clinical differences
Number of subjects: 0
Study 17144179 — intervention group
Group type: EXPERIMENTAL
Intervention: Revisiting market and regulatory incentives regarding race in medicine
Number of subjects: 0
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg, 3 days)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) (25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine, single dose)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg, 3 days)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (in children aged < 5 years)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (in children aged < 5 years)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment failures (in adults)
Number of subjects: 342
Study 14584383 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 5-15 years
Number of subjects: 342
Study 10928213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive and action strategies
Number of subjects: 0
Study 10928213 — intervention group
Group type: COMPARATOR
Intervention: Cognitive strategies
Number of subjects: 0
Study 10928213 — intervention group
Group type: COMPARATOR
Intervention: Action oriented strategies
Number of subjects: 0
Study 8735151 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tones with a 4.5 s interstimulus interval (ISI)
Number of subjects: 26
Study 8735151 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant tones with a 0.5 s ISI
Number of subjects: 26
Study 1356480 — intervention group
Group type: COMPARATOR
Intervention: R1 resection
Number of subjects: 192
Study 1356480 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 resection
Number of subjects: 192
Study 1356480 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 resection by Japanese instructor
Number of subjects: 192
Study 1356480 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 resection by Dutch supervisors
Number of subjects: 192
Study 3863847 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Floss
Number of subjects: 34